Evidence map›Paper›PMID 39283414›Full record

ReviewEJNMMI radiopharmacy and chemistry2024

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Peter Jh Scott, Ivan Penuelas, Ana Rey, Silvio Aime, Pillai M R Ambikalmajan, Ines Farinha Antunes, Frederik Cleeren, Zhaofei Liu, Beverley Ellis, Maryke Kahts and 9 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. High-efficiency [EJNMMI radiopharmacy and chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Peter Jh ScottUniversity of Michigan, Ann Arbor, MI, USA.
Ivan PenuelasUniversity Clinic of Navarra, Pamplona, Spain.
Ana ReyUniversidad de la Republica, Montevideo, Uruguay.
Silvio AimeUniversity of Torino, Torino, Italy.
Pillai M R AmbikalmajanMolecular Group of Companies, Kochi, Kerala, India.
Ines Farinha AntunesUniversity Medical Center Groningen, Groningen, Netherlands.
Frederik CleerenKatholieke Universiteit, Leuven, Belgium.
Zhaofei LiuPeking University, Beijing, China.
Beverley EllisManchester University NHS Foundation Trust, Manchester, UK.
Maryke KahtsSefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa.
Fany Pricile EkoumeUniversity of Yaoundé 1, General Hospital, Yaoundé, Cameroon.
Ivis F ChapleDepartment of Nuclear Engineering, University of Tennessee Knoxville, Knoxville, USA.
Emerson BernardesIPEN, Sao Paulo, Brazil.
Martin BehePaul Scherrer Institute, Villigen, Switzerland.
Ya-Yao HuangPrimo Biotechnology Co. Ltd. Taipei, Taipei, Taiwan.
Renata MikolajczakNational Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, Poland.
Shozo FurumotoResearch Center for Accelerator and Radioisotope Science, Tohoku University, Sendai, Japan.
Amal ElrefaeiInternational Atomic Energy Agency (IAEA) Vienna, Vienna, Austria.
Klaus KopkaInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Faculty of Chemistry and Food Chemistry, School of Science, Technical University Dresden (TUD), Dresden, Germany. k.kopka@hzdr.de.ORCID http://orcid.org/0000-0003-4846-1271

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. MAIN BODY: This selection of highlights provides commentary on 19 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Indexed as

Highlight articlesNuclear medicineRadiochemistryRadiopharmaceutical sciencesRadiopharmacy

Identifiers

PMID39283414
PMCPMC11405612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.